Relationships between resistance to cross-linking agents and glutathione metabolism, aldehyde dehydrogenase isozymes and adenovirus replication in human tumour cell lines.
In a panel of 10 human tumour cell lines with no prior exposure to drugs in vitro, resistance to cisplatin correlated with resistance to the nitrogen mustard derivatives Asta Z-7557 (mafosfamide, an activated form of cyclophosphamide), melphalan and chlorambucil. Simultaneous treatment with DL-buthionine-S,R-sulfoximine did not enhance the toxicity of cisplatin or Asta Z-7557, and no correlation was found between drug resistance and cellular levels of metallothioneins (as judged by sensitivity to cadmium chloride), glutathione (GSH), GSH reductase, GSH transferase, or gamma-glutamyltranspeptidase. The two cell lines most resistant to Asta Z-7557 expressed aldehyde dehydrogenase cytosolic isozyme 1, found also in normal ovary, but not isozyme 3. Treatment of resistant cells with cisplatin or Asta Z-7557 inhibited cellular DNA synthesis and replication of adenovirus 5 to a lesser extent than in sensitive cells. The virus could be directly inactivated by both drugs prior to infection, subsequent replication being inhibited to the same extent in sensitive and resistant cells. In contrast to Asta Z-7557 and other DNA damaging agents, cisplatin was much more toxic to adenovirus (D37 0.022-0.048 microM) than to cells (D37 0.25-2.5 microM). The adenovirus 5 mutant Ad5ts125 having a G----A substitution was even more sensitive to cisplatin (D37 7-8 nM) than wild type virus and another mutant. Cisplatin was detoxified less by sonicated resistant resistant cells than sensitive cells, as judged by inactivation of Ad5ts125 added to the reaction mixture. It can be inferred that (i) the major differences in cellular resistance to cisplatin and Asta Z-7557 in the present material did not involve enhanced DNA repair or protection by metallothioneins or GSH, but were associated with the ability to continue cellular and viral DNA synthesis during treatment, (ii) resistance was not associated with less template damage, and (iii) the adenovirus genome may be a suitable probe for predicting tumour resistance to cisplatin and for elucidating the DNA sequence dependence of cisplatin toxicity.
Parsons
P G
PG
Queensland Institute of Medical Research, Herston, Brisbane, Australia.
Lean
J
J
Kable
E P
EP
Favier
D
D
Khoo
S K
SK
Hurst
T
T
Holmes
R S
RS
Bellet
A J
AJ
D000260:Adenoviruses, Human / Q000254:growth & development*; D000444:Aldehyde Dehydrogenase / Q000378:metabolism*; D002104:Cadmium / Q000494:pharmacology; D019256:Cadmium Chloride; D002699:Chlorambucil / Q000494:pharmacology; D002945:Cisplatin / Q000494:pharmacology; D003432:Cross-Linking Reagents / Q000494:pharmacology*; D003520:Cyclophosphamide / Q000031:analogs & derivatives / Q000494:pharmacology; D004249:DNA Damage; D004351:Drug Resistance; D005978:Glutathione / Q000378:metabolism*; D006801:Humans; D007527:Isoenzymes / Q000378:metabolism; D008558:Melphalan / Q000494:pharmacology; D008668:Metallothionein / Q000378:metabolism; D014407:Tumor Cells, Cultured; D014779:Virus Replication
D003432:Cross-Linking Reagents; D007527:Isoenzymes; D002104:Cadmium; D002699:Chlorambucil; C037933:Asta Z 7557; D003520:Cyclophosphamide; D008668:Metallothionein; D000444:Aldehyde Dehydrogenase; D005978:Glutathione; D019256:Cadmium Chloride; D002945:Cisplatin; D008558:Melphalan